Your session is about to expire
← Back to Search
Brentuximab + Chemotherapy + Radiation for Hodgkin Lymphoma
Study Summary
This trial is testing a new combination of drugs and radiation therapy to treat Hodgkin lymphoma in young patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function is good based on tests.My liver tests are within the normal range for my age.I have Hodgkin Lymphoma that hasn't been treated yet, but I may have had emergency radiation or steroids for a short time.I agree to use effective birth control during the study.I have previously been treated for Hodgkin lymphoma.My organs are not functioning properly.I am unable or unwilling to give my consent to participate.I am 18 years old or younger.My Hodgkin's lymphoma does not express CD30.I am a woman who has started menstruating and have a negative pregnancy test.My cancer is at an advanced stage, but not the earliest or final stages.
- Group 1: Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there additional studies being conducted involving brentuximab vedotin?
"At the present moment, there are 1,457 studies investigating brentuximab vedotin. Of those, 314 have reached Phase 3 of trials. The primary site for these research efforts is Bethesda in Maryland; however, 52769 different locations around the world are conducting their own investigations into this medication."
To what extent are hospitals in this state administering this experiment?
"The current clinical trial is recruiting patients from Lucile Packard Children's Hospital Stanford University in Palo Alto, California, Dana-Farber Harvard Cancer Center in Boston, Massachusetts, and the Mass General Hospital Cancer Centre located in Peoria Illinois. In addition to these three sites there are an additional 6 locations involved with this study."
For what clinical purposes is brentuximab vedotin commonly recommended?
"Brentuximab vedotin is a widely accepted method for treating pheochromocytomas. It has also been found to be useful in managing ulcerative colitis, varicella-zoster virus acute retinal necrosis and multiple myeloma."
Is this exploration a pioneering endeavor?
"Since its first clinical trial, sponsored by Alfacell in 1997 and involving 300 patients, brentuximab vedotin has gained approval as a phase 3 drug. Currently there are 1457 active studies occurring across 3045 cities and 81 nations."
Is participation in this research program available at the present moment?
"This clinical investigation is no longer recruiting individuals. It was initially posted on August 12th, 2013 and its most recent update happened on August 15th, 2022. If you are still looking for a suitable trial to enter, there are 1723 trials presently enrolling patients affected by hodgkin disease and 1457 studies relying upon brentuximab vedotin that could be of use."
How many participants is the clinical trial currently accommodating?
"This research is temporarily closed, having first been posted on August 12th 2013 and last updated 8/15/2022. For those still looking to take part in a clinical trial for hodgkin disease, there are 1723 studies accepting participants at this time with 1457 trials specific to brentuximab vedotin actively recruiting patients."
Has brentuximab vedotin been endorsed by the FDA?
"Brentuximab vedotin is rated a 2 on the safety scale due to its Phase 2 status. While there are reports of its safety, no studies have yet proven any efficacy from this drug."
Share this study with friends
Copy Link
Messenger